7Felberg RA, Burgin WS, Grotta JC. Neurop rotection and the is- chemic cascade. C-NS Spectrums, 2005, 10(5): 52-58.
8Tanaka M. Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent. Nippon Yakurigaku Zasshi, 2002, 119(5): 301-308.
9Takabatake Y, Uno E, Wakamatsu K, et al. The clinical effect of combination therapy with edaravone and sodi- urn ozagrel for acute cerebral infarction. No To Shinkei, 2003, 55(7): 589-593.
10Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of re- ports of randomized clinical trials: is blinding necessary. Control Clin Trials, 1996, 17(1): 1-12.
